47 patents
Utility
Niclosamide Particles and Uses Thereof
28 Dec 23
The disclosure provides compositions and methods for use of compositions that include particles comprising at least 30% niclosamide by weight, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the particles have one or more of: (i) a mean bulk density (not tapped) of less than 0.40 g/cm3; 00 a mean tapped density of less than 0.55 g/cm 3 ; and/or (in) a specific surface area (SSA) of at least 3.6 m2/g.
Michael BALTEZOR, Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Aranza Barreda ABARCA
Filed: 8 Sep 21
Utility
Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles
23 Nov 23
Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.
Gere S. diZerega, Michael Baltezor, Charles J. Decedue, Sam Campbell, Matthew McClorey, Marc Iacobucci, Holly Maulhardt
Filed: 13 Jul 23
Utility
d4zre4vz yx7ub7czta7cidkf6e3cpadfkyor6utiaupqli5u5uyx0m
16 Nov 23
Particles of at least 95% by weight of sorafenib, or a pharmaceutically acceptable salt thereof are provided, wherein the particles have a specific surface area (SSA) of at least 2 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm, as are methods for their use, and methods for making such particles.
Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Michael BALTEZOR, Gere DIZEREGA, Aranza Barreda ABARCA, Shelby CLARK
Filed: 18 Jul 23
Utility
ber4bg7xuuyom99efgfj5hq5u9
11 May 23
Compositions of particles having at least 95% by weight of niraparib and a specific surface area (SSA) of at least 5 m2/g, methods for their use, and methods for their production are provided.
Jacob SITTENAUER, Aranza Barreda ABARCA, Shelby CLARK, Joseph FARTHING, Mark WILLIAMS, Gere DIZEREGA, Michael BALTEZOR
Filed: 8 Nov 22
Utility
d1tpo7snihp8w58opidj4nu t1fxd3jnemzxx95f6mzo90nrj3dk6l3
11 May 23
Compositions of particles having at least 95% by weight of rucaparib and a specific surface area (SSA) of at least 12 m2/g, methods for their use, and methods for their production are provided.
Jacob SITTENAUER, Aranza Barreda ABARCA, Shelby CLARK, Joseph FARTHING, Mark WILLIAMS, Gere DIZEREGA, Michael BALTEZOR
Filed: 8 Nov 22
Utility
nrfgiwvr3g7qnodgyud qwj8atdidg6
13 Apr 23
Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.
Gere S. diZerega, Michael Baltezor, Charles J. Decedue, Sam Campbell, Matthew McClorey, Marc Iacobucci, Holly Maulhardt
Filed: 12 Oct 22
Utility
hdqpid8e2iuh9j1xlkiywe2 dluu1p7
21 Feb 23
Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents.
Gere S. Dizerega, Michael Baltezor, Sam Campbell, Charles J. Decedue, Matthew McClorey
Filed: 28 May 21
Utility
zg70nwi 0dq8s17xcbpub8b8pu5gw
13 Dec 22
Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.
Gere S. diZerega, Michael Baltezor, Charles J. Decedue, Sam Campbell, Matthew McClorey, Marc Iacobucci, Holly Maulhardt
Filed: 10 May 21
Utility
na0jikiwcdfcu7udtdgone3m5ifk2bm
24 Nov 22
The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.
Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Michael BALTEZOR, Gere DIZEREGA, Aranza Barreda ABARCA, Shelby CLARK
Filed: 14 Jul 22
Utility
jkcd9dkbiw2ki56heh94258meeqtn7lvik8jt6fxkwkeu482joa6p
4 Oct 22
Disclosed herein are methods for treating solid tumors by direct injection into the tumors of chemotherapeutic particles, methods for inhibiting tumor metastasis by administering chemotherapeutic particles to a subject having a tumor, and compositions that include chemotherapeutic particles, small amounts of a polysorbate, and a carrier.
Mike Baltezor, Gere diZerega, Charles Decedue, Sam Campbell, Matt McClorey
Filed: 3 Apr 20
Utility
uao7f8yqo58qgteeow646y7gyw7lhdgzp0sly
4 Aug 22
The disclosure provides particles of at least 95% by weight of sorafenib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 2 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm, methods for their use, and methods for making such particles.
Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Michael BALTEZOR, Gere DIZEREGA, Aranza Barreda ABARCA, Shelby CLARK
Filed: 21 Jul 21
Utility
lh8udyhj5lt oav3l0kums7194pyhf86m3yg3m9y
5 Apr 22
The present disclosure provides an apparatus and methods of use for isolating particles.
Bala Subramaniam, Jahna Espinosa, Gregory F. Johnson, Jacob M. Sittenauer, Joseph S. Farthing
Filed: 6 Jun 16
Utility
t9c70kc5dw0u0lhqgo3t7t5hgs9ttu9ot
31 Mar 22
Disclosed herein are methods for treating and inhibiting the recurrence of bladder cancer by local administration of compositions comprising taxane particles such as docetaxel particles.
Gere S. DIZEREGA, Michael BALTEZOR, Charles DECEDUE, Sam CAMPBELL, Matthew MCCLOREY
Filed: 1 Oct 21
Utility
fh48as753nntvovlvnl4g9pmpb5tt6xtd9dvu9mph
17 Feb 22
Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents.
Gere S. DIZEREGA, Michael BALTEZOR, Sam CAMPBELL, Charles J. DECEDUE, Matthew MCCLOREY
Filed: 28 May 21
Utility
4vnj2xjw8uptfd n4f4ffx9ujwmod9izf68oinrmy9kcsip4mb61pi
27 Jan 22
The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.
Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Michael BALTEZOR, Gere DIZEREGA, Aranza Barreda ABARCA, Shelby CLARK
Filed: 21 Jul 21
Utility
lc0v1wcp5jmfv18d0cvjwvee0u 1j
23 Dec 21
Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g.
Michael BALTEZOR, Joseph FARTHING, Jake SITTENAUER, Jahna ESPINOSA, Samuel CAMPBELL, Matthew MCCLOREY, Julia K. FISCHER, Mark D. WILLIAMS, Gary E. CLAPP
Filed: 7 Sep 21
Utility
rc0fjrvjnkzzflhczoepd0oei6my0f1xdcya3rjz33mkx894cr655wqf
16 Dec 21
The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.
Mark WILLIAMS, Jacob SITTENAUER, Shelby CLARK, Joseph FARTHING, Michael BALTEZOR, Matthew MCCLOREY
Filed: 13 Aug 21
Utility
44g36nbaq7wkuarr2en9o4b2r
2 Nov 21
Disclosed herein are compositions and methods for treating lung disorders including lung tumors by pulmonary administration of compositions comprising taxane particles such as docetaxel or paclitaxel particles.
Michael Baltezor, Matthew McClorey, William Johnston, Gere S. diZerega, James Verco
Filed: 31 Oct 19
Utility
hrn i29nfkk5p4dnvpo9lmsiu2vqoywxs5en0ap151ny7oxgr
21 Sep 21
Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g.
Michael Baltezor, Joseph Farthing, Jake Sittenauer, Jahna Espinosa, Samuel Campbell, Matthew McClorey, Julia K. Fischer, Mark D. Williams, Gary E. Clapp
Filed: 30 Oct 19
Utility
02gx55tq3 f05dkax4jg46f14sshscqik
31 Aug 21
The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.
Mark Williams, Jacob Sittenauer, Shelby Clark, Joseph Farthing, Michael Baltezor, Matthew McClorey
Filed: 28 Sep 18